TheStreet upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a c+ rating to a b- rating in a research note published on Monday, TheStreetRatingsTable reports.
Other research analysts have also issued research reports about the company. Piper Jaffray Companies set a $435.00 price objective on Regeneron Pharmaceuticals and gave the company a buy rating in a report on Tuesday, October 8th. JPMorgan Chase & Co. restated a hold rating and issued a $375.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, November 6th. Evercore ISI reaffirmed a buy rating and set a $395.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, November 11th. Bank of America assumed coverage on Regeneron Pharmaceuticals in a research report on Wednesday, October 16th. They set a neutral rating and a $325.00 target price for the company. Finally, ValuEngine downgraded Regeneron Pharmaceuticals from a hold rating to a sell rating in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $384.74.
Shares of NASDAQ:REGN opened at $368.81 on Monday. The company has a current ratio of 4.03, a quick ratio of 3.27 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $40.51 billion, a PE ratio of 18.63, a P/E/G ratio of 1.62 and a beta of 1.19. Regeneron Pharmaceuticals has a 1 year low of $271.37 and a 1 year high of $442.00. The firm has a fifty day moving average price of $331.72 and a 200 day moving average price of $307.22.
Regeneron Pharmaceuticals announced that its Board of Directors has approved a share buyback program on Tuesday, November 5th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to buy up to 2.9% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.
In other news, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $340.44, for a total value of $340,440.00. Following the completion of the transaction, the director now owns 10,323 shares in the company, valued at approximately $3,514,362.12. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Chairman P Roy Vagelos sold 22,149 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $363.83, for a total transaction of $8,058,470.67. Insiders sold a total of 213,923 shares of company stock valued at $63,262,696 in the last quarter. Corporate insiders own 11.84% of the company’s stock.
Several institutional investors have recently modified their holdings of REGN. Bridger Capital Management LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter worth about $30,000. HM Payson & Co. acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. Coastal Capital Group Inc. acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $38,000. Horan Capital Advisors LLC. acquired a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $47,000. Finally, Sumitomo Mitsui Financial Group Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $49,000. Institutional investors and hedge funds own 66.48% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: What is a put option?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.